SEATTLE, June 11, 2013 /PRNewswire/ -- Natural
Molecular Testing Corporation (Natural Molecular, NMTC), a
privately-owned company providing groundbreaking clinical
diagnostic molecular testing and services in the medical genomics
field, announced today the launch of their laboratory developed
comprehensive Personalized Medicine Panel. This cardiac panel,
commercialized by Natural Molecular, is comprised of 42 targets and
built using Luminex Corporation's (NASDAQ: LMNX) xMAP®
Technology.
(Logo:
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
"Our goal is to bring the latest advancements in medical science
and technology to help clinicians do one simple thing: provide the
best possible care for their patients," said Beau R. Fessenden, CEO of Natural Molecular. "By
converting to Luminex's xMAP technology, we can improve our
throughput and workflow efficiency with more comprehensive and
highly sensitive assays that set us apart in the marketplace. The
flexibility and high throughput of the Luminex platform combined
with the ability to add additional biomarkers make the technology
unique and best suited to our expanding needs."
Each year more than 2 million Americans are hospitalized due to
adverse drug reactions which lead to an estimated 100,000
deaths.1 Molecular testing allows physicians to
diagnose genetic abnormalities in patients, providing
guidance in selecting optimal medications and doses of medications
while minimizing risk for a wide variety of common conditions such
as chronic heart disease and pain.
"We are excited to be expanding our relationship with Natural
Molecular in the important area of pharmacogenomics," said
Patrick Balthrop, president and CEO
of Luminex. "It is valuable for a physician to know whether a
specific therapeutic compound will be most beneficial for a
particular patient. Through the use of genetic testing, driven by
the throughput and scalability of our technology and the unique
services of NMTC, our two companies are working together to
optimize patient outcomes and lower overall health-care costs. We
look forward to expanding opportunities with Natural Molecular, a
leader in pharmacogenomic testing."
The financial terms of the multi-year collaboration and license
agreement were not disclosed.
About Personalized Medicine Panel
Natural Molecular's
new comprehensive Personalized Medicine Panel features a simple
laboratory workflow based on Luminex's flexible xMAP Technology.
Multiplexing a comprehensive set of biomarkers together from a
single sample offers significant improvements in testing efficiency
saving valuable time and increasing throughput. The panel includes
the following:
CYP450 2C19
CYP450 2C9
CYP450 2D6
CYP450 3A4
CYP450 3A5
ABCB1
VKORC1
MTHFR
Factor II
Factor V Leiden
About Natural Molecular Testing Corporation
Natural Molecular Testing Corporation (NMTC) is a
privately-owned, high-complexity molecular testing facility. NMTC
provides comprehensive genetic testing solutions that improve
patient care through the latest breakthroughs in genomic
technology.
For more information about Natural Molecular Testing Corp.,
visit www.naturalmolecular.com
About Luminex Corporation (NASDAQ: LMNX)
Luminex is committed to applying its passion for innovation
toward advancing healthcare and research worldwide. The company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase chain
reaction (PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and researchers.
Luminex's technology is commercially available worldwide and in use
in leading clinical laboratories, as well as major pharmaceutical,
diagnostic, biotechnology and life-science companies. Luminex is
meeting the needs of customers in markets as diverse as clinical
diagnostics, pharmaceutical drug discovery, biomedical research
including genomic and proteomic research, personalized medicine,
biodefense research and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using
award winning technology, please visit
http://www.luminexcorp.com/.
References:
- "Cytochrome P450 Enzyme Genotyping: Optimizing Patient Care
Through Pharmacogenetics." Communique 30.9 (2005):
Mayo Medical Laboratories.
http://www.mayomedicallaboratories.com/
Natural Molecular Contact:
Media:
Ken Wallace
Natural Molecular Testing Corp
Director of Business Development
1-888-442-8881
Luminex Contact:
Investors:
Matt Scalo
Luminex Corporation
mscalo@luminexcorp.com
512.336.3587
Media:
Mimi Torrington
Luminex Corporation
mtorrington@luminexcorp.com
512.219.8020
SOURCE Natural Molecular Testing Corporation; Luminex
Corporation